Canaccord Genuity Starts Ultragenyx Pharma (RARE) at Buy

Canaccord Genuity initiated coverage on Ultragenyx Pharma (NASDAQ: RARE) with a Buy rating and a price target of $60.00.

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $48.65 yesterday.

You May Also Be Interested In

• Oppenheimer Assumes Inova Technology, Inc. (INVA) at Outperform
• Ultragenyx Pharma (RARE) PT Raised to $39 at Cantor Fitzgerald on FAYUVI Approval
• Desjardins Resumes Primaris REIT (PMZ-U:CN) at Buy